The European Commission (EC) has approval for 鈥檚 Skyrizi (risankizumab, 600mg intravenous [IV] induction and 360 mg subcutaneous [SC] maintenance therapy) to treat moderately to severely active Crohn鈥檚 disease in adult patients.
Skyrizi is indicated for usage in such patients with insufficient response, lost response or were not tolerant to standard or biologic therapy.
The regulatory agency granted approval based on findings from the international Phase III programme, which included ADVANCE induction, MOTIVATE induction and FORTIFY maintenance trials.
The three multicentre, randomised, double-blind, placebo-controlled Phase III trials analysed the efficacy, safety and tolerability of Skyrizi.
A substantially higher proportion of subjects who received Skyrizi attained the co-primary endpoints of clinical remission (per SF/AP) and endoscopic response in all the trials.
Additionally, participants who were treated with Skyrizi had mucosal healing and endoscopic remission.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSafety data of Skyrizi in Crohn鈥檚 disease from these trials were in line with the already reported safety profile of the therapy without any new safety risks observed.
An inhibitor of interleukin-23 (IL-23), Skyrizi hinders IL-23 by attaching to its p19 subunit.
The therapy is part of a partnership between and , with the former advancing its development and marketing across the globe.
In the European Union, Skyrizi also received approval to treat adults with psoriasis and psoriatic arthritis.
AbbVie research and development senior vice-president and chief scientific officer Thomas Hudson said: 鈥淭here are still many patients suffering from debilitating symptoms associated with Crohn鈥檚 disease, such as abdominal pain and stool frequency, which is why we鈥檝e embraced the challenge of serving these patients in need.
鈥淭he approval of Skyrizi in the European Union is a significant milestone in our pursuit to expand our IBD portfolio.鈥�
The latest development comes after the US Food and Drug Administration accepted the company鈥檚 Biologics License Application of epcoritamab (DuoBody-CD3xCD20) for treating relapsed/refractory large B-cell lymphoma in adults, for priority review.
